Optimi Health Enters Australian Medical MDMA And Psilocybin Market With Mind Medicine Australia Distribution Agreement Post published:March 1, 2023 Post category:Press Release
Optimi Health Submits Phase I Clinical Trial Application Combining The Use Of Proprietary Psilocybin and MDMA Drug Candidates In Healthy Therapists Post published:February 7, 2023 Post category:Press Release
Optimi Health Completes First Production of Novel MDMA Drug Candidate OPTI-MHCL Post published:February 6, 2023 Post category:Press Release
Optimi Health Expands Functional Mushroom Sales Network With Additional Brokers, Distribution Agreements Post published:January 18, 2023 Post category:Press Release
Optimi Health Announces Re-Appointments to Board of Directors Post published:January 12, 2023 Post category:Press Release
Optimi Health Announces Closing of Strategic Non-Brokered Private Placement Post published:October 11, 2022 Post category:Press Release
Alberta Puts Patients First By Regulating Psychedelic Therapy: Optimi Health Post published:October 7, 2022 Post category:Press Release
Optimi Health, ATMA Journey Centers To Proceed With Phase I Natural Psilocybin and MDMA Clinical Trial Application to Health Canada Post published:September 22, 2022 Post category:Press Release
Optimi Health Completes Largest Legal Natural Psilocybin Harvest in Canadian History Post published:September 8, 2022 Post category:Press Release
Optimi Health Signs First International Mushroom Supply Agreement with UK-based Avida Global Post published:September 7, 2022 Post category:Press Release